Table of Content

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights

2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology

3. Executive Summary

4. Market Overview
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunity
4.3. Global CAR T-cell Therapy Market Forecast
4.4. Global CAR T-cell Therapy Market Outlook

5. Market Outlook
5.1. Key Industry Events
5.2. Diseases Epidemiology
5.3. Product Pipeline Analysis
5.4. Impact of COVID-19 Pandemic

6. Global CAR T-cell Therapy Market Analysis, by Product Type
6.1. Introduction
6.2. Global CAR T-cell Therapy Market Value Share Analysis, by Product Type
6.3. Global CAR T-cell Therapy Market Forecast, by Product Type
6.3.1. Axicabtagene Ciloleucel
6.3.2. Tisagenlecleucel
6.3.3. Brexucabtagene Autoleucel
6.3.4. Lisocabtagene Maraleucel
6.3.5. Idecabtagene Vicleucel
6.3.6. Others
6.4. Global CAR T-cell Therapy Market Analysis, by Product Type
6.5. Global CAR T-cell Therapy Market Attractiveness Analysis, by Product Type

7. Global CAR T-cell Therapy Market Analysis, by Indications
7.1. Introduction
7.2. Global CAR T-cell Therapy Market Value Share Analysis, by Indication
7.3. Global CAR T-cell Therapy Market Forecast, by Indication
7.3.1. Acute Lymphocytic Leukemia
7.3.2. Diffuse Large B-Cell Lymphoma
7.3.3. Follicular Lymphoma
7.3.4. Mantle Cell Lymphoma
7.3.5. Multiple Myeloma
7.3.6. Others
7.4. Global CAR T-cell Therapy Market Analysis, by Indication
7.5. Global CAR T-cell Therapy Market Attractiveness Analysis, by Indication

8. Global CAR T-cell Therapy Market Analysis, by End-user
8.1. Introduction
8.2. Global CAR T-cell Therapy Market Value Share Analysis, by End-user
8.3. Global CAR T-cell Therapy Market Forecast, by End-user
8.3.1. Hospitals
8.3.2. Cancer Treatment Centers
8.4. Global CAR T-cell Therapy Market Analysis, by End-user
8.5. Global CAR T-cell Therapy Market Attractiveness Analysis, by End-user

9. Global CAR T-cell Therapy Market Analysis, by Region
9.1. Global CAR T-cell Therapy Market Analysis, by Region
9.2. Global CAR T-cell Therapy Market Value Share Analysis, by Region
9.3. Global CAR T-cell Therapy Market Forecast, by Region
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa

10. North America CAR T-cell Therapy Market Analysis
10.1. North America CAR T-cell Therapy Market Overview
10.2. North America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Country
10.3. North America CAR T-cell Therapy Market Forecast, by Country
10.3.1. U.S.
10.3.2. Canada
10.4. North America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Product Type
10.5. North America CAR T-cell Therapy Market Forecast, by Product Type
10.5.1. Axicabtagene Ciloleucel
10.5.2. Tisagenlecleucel
10.5.3. Brexucabtagene Autoleucel
10.5.4. Lisocabtagene Maraleucel
10.5.5. Idecabtagene Vicleucel
10.5.6. Others
10.6. North America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Indications
10.7. North America CAR T-cell Therapy Market Forecast, by Indication
10.7.1. Acute Lymphocytic Leukemia
10.7.2. Diffuse Large B-Cell Lymphoma
10.7.3. Follicular Lymphoma
10.7.4. Mantle Cell Lymphoma
10.7.5. Multiple Myeloma
10.7.6. Others
10.8. North America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by End-user
10.9. North America CAR T-cell Therapy Market Forecast, by End-user
10.9.1. Hospitals
10.9.2. Cancer Treatment Centers

11. Europe CAR T-cell Therapy Market Analysis
11.1. Europe CAR T-cell Therapy Market Overview
11.2. Europe CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.3. Europe CAR T-cell Therapy Market Forecast, by Country/Sub-region
11.3.1. Germany
11.3.2. France
11.3.3. U.K.
11.3.4. Italy
11.3.5. Spain
11.3.6. Rest of Europe
11.4. Europe CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Product Type
11.5. Europe CAR T-cell Therapy Market Forecast, by Product Type
11.5.1. Axicabtagene Ciloleucel
11.5.2. Tisagenlecleucel
11.5.3. Brexucabtagene Autoleucel
11.5.4. Lisocabtagene Maraleucel
11.5.5. Idecabtagene Vicleucel
11.5.6. Others
11.6. Europe CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Indication
11.7. Europe CAR T-cell Therapy Market Forecast, by Indication
11.7.1. Acute Lymphocytic Leukemia
11.7.2. Diffuse Large B-Cell Lymphoma
11.7.3. Follicular Lymphoma
11.7.4. Mantle Cell Lymphoma
11.7.5. Multiple Myeloma
11.7.6. Others
11.8. Europe CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by End-user
11.9. Europe CAR T-cell Therapy Market Forecast, by End-user
11.9.1. Hospitals
11.9.2. Cancer Treatment Centers

12. Asia Pacific CAR T-cell Therapy Market Analysis
12.1. Asia Pacific CAR T-cell Therapy Market Overview
12.2. Asia Pacific CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.3. Asia Pacific CAR T-cell Therapy Market Forecast, by Country/Sub-region
12.3.1. China
12.3.2. Japan
12.3.3. India
12.3.4. Australia & New Zealand
12.3.5. Rest of Asia Pacific
12.4. Asia Pacific CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Product Type
12.5. Asia Pacific CAR T-cell Therapy Market Forecast, by Product Type
12.5.1. Axicabtagene Ciloleucel
12.5.2. Tisagenlecleucel
12.5.3. Brexucabtagene Autoleucel
12.5.4. Lisocabtagene Maraleucel
12.5.5. Idecabtagene Vicleucel
12.5.6. Others
12.6. Asia Pacific CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Indication
12.7. Asia Pacific CAR T-cell Therapy Market Forecast, by Indication
12.7.1. Acute Lymphocytic Leukemia
12.7.2. Diffuse Large B-Cell Lymphoma
12.7.3. Follicular Lymphoma
12.7.4. Mantle Cell Lymphoma
12.7.5. Multiple Myeloma
12.7.6. Others
12.8. Asia Pacific CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by End-user
12.9. Asia Pacific CAR T-cell Therapy Market Forecast, by End-user
12.9.1. Hospitals
12.9.2. Cancer Treatment Centers
13. Latin America CAR T-cell Therapy Market Analysis
13.1. Latin America CAR T-cell Therapy Market Overview
13.2. Latin America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Country/Sub-region
13.3. Latin America CAR T-cell Therapy Market Forecast, by Country/Sub-region
13.3.1. Brazil
13.3.2. Mexico
13.3.3. Rest of Latin America
13.4. Latin America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Product Type
13.5. Latin America CAR T-cell Therapy Market Forecast, by Product Type
13.5.1. Axicabtagene Ciloleucel
13.5.2. Tisagenlecleucel
13.5.3. Brexucabtagene Autoleucel
13.5.4. Lisocabtagene Maraleucel
13.5.5. Idecabtagene Vicleucel
13.5.6. Others
13.6. Latin America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Indication
13.7. Latin America CAR T-cell Therapy Market Forecast, by Indication
13.7.1. Acute Lymphocytic Leukemia
13.7.2. Diffuse Large B-Cell Lymphoma
13.7.3. Follicular Lymphoma
13.7.4. Mantle Cell Lymphoma
13.7.5. Multiple Myeloma
13.7.6. Others
13.8. Latin America CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by End-user
13.9. Latin America CAR T-cell Therapy Market Forecast, by End-user
13.9.1. Hospitals
13.9.2. Cancer Treatment Centers

14. Middle East & Africa CAR T-cell Therapy Market Analysis
14.1. Middle East & Africa CAR T-cell Therapy Market Overview
14.2. Middle East & Africa CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Country/Sub-region
14.3. Middle East & Africa CAR T-cell Therapy Market Forecast, by Country/Sub-region
14.3.1. GCC Countries
14.3.2. South Africa
14.3.3. Rest of Middle East & Africa
14.4. Middle East & Africa CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Product Type
14.5. Middle East & Africa CAR T-cell Therapy Market Forecast, by Product Type
14.5.1. Axicabtagene Ciloleucel
14.5.2. Tisagenlecleucel
14.5.3. Brexucabtagene Autoleucel
14.5.4. Lisocabtagene Maraleucel
14.5.5. Idecabtagene Vicleucel
14.5.6. Others
14.6. Middle East & Africa CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by Indication
14.7. Middle East & Africa CAR T-cell Therapy Market Forecast, by Indication
14.7.1. Acute Lymphocytic Leukemia
14.7.2. Diffuse Large B-Cell Lymphoma
14.7.3. Follicular Lymphoma
14.7.4. Mantle Cell Lymphoma
14.7.5. Multiple Myeloma
14.7.6. Others
14.8. Middle East & Africa CAR T-cell Therapy Market Value Share and Attractiveness Analysis, by End-user
14.9. Middle East & Africa CAR T-cell Therapy Market Forecast, by End-user
14.9.1. Hospitals
14.9.2. Cancer Treatment Centers

15. Competition Landscape
15.1. Competition Matrix
15.2. Company Profiles
15.2.1. Pfizer Inc.
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Product Portfolio
15.2.1.3. Financial Overview
15.2.1.4. SWOT Analysis
15.2.1.5. Strategic Overview
15.2.2. Novartis AG
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Product Portfolio
15.2.2.3. Financial Overview
15.2.2.4. SWOT Analysis
15.2.2.5. Strategic Overview
15.2.3. Bristol-Myers Squibb
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Product Portfolio
15.2.3.3. Financial Overview
15.2.3.4. SWOT Analysis
15.2.3.5. Strategic Overview
15.2.4. Amgen, Inc.
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Product Portfolio
15.2.4.3. Financial Overview
15.2.4.4. SWOT Analysis
15.2.4.5. Strategic Overview
15.2.5. Sorrento Therapeutics, Inc.
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Product Portfolio
15.2.5.3. Financial Overview
15.2.5.4. SWOT Analysis
15.2.5.5. Strategic Overview
15.2.6. Johnson & Johnson Services, Inc.
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Product Portfolio
15.2.6.3. Financial Overview
15.2.6.4. SWOT Analysis
15.2.6.5. Strategic Overview
15.2.7. Gilead Sciences, Inc.
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Product Portfolio
15.2.7.3. Financial Overview
15.2.7.4. SWOT Analysis
15.2.7.5. Strategic Overview
15.2.8. Merck & Co., Inc.
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Product Portfolio
15.2.8.3. Financial Overview
15.2.8.4. SWOT Analysis
15.2.8.5. Strategic Overview
15.2.9. bluebird bio, Inc.
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Product Portfolio
15.2.9.3. Financial Overview
15.2.9.4. SWOT Analysis
15.2.9.5. Strategic Overview



List of Figures

List of Figures

Figure 01: Global CAR T-cell Therapy Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Global CAR T-cell Therapy Market Value Share, by Product Type, 2020

Figure 03: Global CAR T-cell Therapy Market Value Share, by Indication, 2020

Figure 04: Global CAR T-cell Therapy Market Value Share, by End-user Type, 2020

Figure 05: Global CAR T-cell Therapy Market Value Share, by Region, 2020

Figure 06: Global Car T-Cell Therapy Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 07: Global Car T-Cell Therapy Market Value (US$ Mn), by Axicabtagene Ciloleucel, 2017–2031

Figure 08: Global Car T-Cell Therapy Market Value (US$ Mn), by Tisagenlecleucel, 2017–2031

Figure 09: Global Car T-Cell Therapy Market Value (US$ Mn), by Brexucabtagene Autoleucel, 2017–2031

Figure 10: Global Car T-Cell Therapy Market Value (US$ Mn), by Lisocabtagene Maraleucel, 2017–2031

Figure 11: Global Car T-Cell Therapy Market Value (US$ Mn), by Idecabtagene Vicleucel, 2017–2031

Figure 12: Global Car T-Cell Therapy Market Value (US$ Mn), by Others, 2017–2031

Figure 13: Global Car T-Cell Therapy Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 14: Global Car T-Cell Therapy Market Value Share Analysis, by Indication, 2020 and 2031

Figure 15: Global Car T-Cell Therapy Market Value (US$ Mn), by Acute Lymphocytic Leukemia, 2017–2031

Figure 16: Global Car T-Cell Therapy Market Value (US$ Mn), by Diffuse Large B-cell Lymphoma, 2017–2031

Figure 17: Global Car T-Cell Therapy Market Value (US$ Mn), by Follicular Lymphoma, 2017–2031

Figure 18: Global Car T-Cell Therapy Market Value (US$ Mn), by Mantle Cell Lymphoma, 2017–2031

Figure 19: Global Car T-Cell Therapy Market Value (US$ Mn), by Multiple Myeloma, 2017–2031

Figure 20: Global Car T-Cell Therapy Market Value (US$ Mn), by Others, 2017–2031

Figure 21: Global Car T-Cell Therapy Market Attractiveness Analysis, by Indication, 2021–2031

Figure 22: Global Car T-Cell Therapy Market Value Share Analysis, by End-user, 2020 and 2031

Figure 23: Global Car T-Cell Therapy Market Value (US$ Mn), by Hospitals, 2017–2031

Figure 24: Global Car T-Cell Therapy Market Value (US$ Mn), by Cancer Treatment Centers, 2017–2031

Figure 25: Global Car T-Cell Therapy Market Attractiveness Analysis, by End-user, 2021–2031

Figure 26: Global Car T-Cell Therapy Market Value Share Analysis, by Region, 2020 and 2031

Figure 27: Global Car T-Cell Therapy Market Attractiveness Analysis, by Region, 2021-2031

Figure 28: North America CAR T-Cell Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 29: North America CAR T-Cell Therapy Market Value Share (%), by Country, 2020 and 2031

Figure 30: North America CAR T-Cell Therapy Market Attractiveness Analysis, by Country, 2021–2031

Figure 31: North America CAR T-Cell Therapy Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 32: North America CAR T-Cell Therapy Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 33: North America CAR T-Cell Therapy Market Value Share Analysis, by Indication, 2020 and 2031

Figure 34: North America CAR T-Cell Therapy Market Attractiveness Analysis, by Indication, 2021–2031

Figure 35: North America CAR T-Cell Therapy Market Value Share Analysis, by End-user, 2020 and 2031

Figure 36: North America CAR T-Cell Therapy Market Attractiveness Analysis, by End-user, 2021–2031

Figure 37: Europe CAR T-Cell Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 38: Europe CAR T-Cell Therapy Market Value Share (%), by Country/Sub-region, 2020 and 2031

Figure 39: Europe CAR T-Cell Therapy Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 40: Europe CAR T-Cell Therapy Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 41: Europe CAR T-Cell Therapy Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 42: Europe CAR T-Cell Therapy Market Value Share Analysis, by Indication, 2020 and 2031

Figure 43: Europe CAR T-Cell Therapy Market Attractiveness Analysis, by Indication, 2021–2031

Figure 44: Europe CAR T-Cell Therapy Market Value Share Analysis, by End-user, 2020 and 2031

Figure 45: Europe CAR T-Cell Therapy Market Attractiveness Analysis, by End-user, 2021–2031

Figure 46: Asia Pacific CAR T-Cell Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 47: Asia Pacific CAR T-Cell Therapy Market Value Share (%), by Country/Sub-region, 2020 and 2031

Figure 48: Asia Pacific CAR T-Cell Therapy Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 49: Asia Pacific CAR T-Cell Therapy Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 50: Asia Pacific CAR T-Cell Therapy Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 51: Asia Pacific CAR T-Cell Therapy Market Value Share Analysis, by Indication, 2020 and 2031

Figure 52: Asia Pacific CAR T-Cell Therapy Market Attractiveness Analysis, by Indication, 2021–2031

Figure 53: Asia Pacific CAR T-Cell Therapy Market Value Share Analysis, by End-user, 2020 and 2031

Figure 54: Asia Pacific CAR T-Cell Therapy Market Attractiveness Analysis, by End-user, 2021–2031

Figure 55: Latin America CAR T-Cell Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 56: Latin America CAR T-Cell Therapy Market Value Share (%), by Country/Sub-region, 2020 and 2031

Figure 57: Latin America CAR T-Cell Therapy Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 58: Latin America CAR T-Cell Therapy Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 59: Latin America CAR T-Cell Therapy Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 60: Latin America CAR T-Cell Therapy Market Value Share Analysis, by Indication, 2020 and 2031

Figure 61: Latin America CAR T-Cell Therapy Market Attractiveness Analysis, by Indication, 2021–2031

Figure 62: Latin America CAR T-Cell Therapy Market Value Share Analysis, by End-user, 2020 and 2031

Figure 63: Latin America CAR T-Cell Therapy Market Attractiveness Analysis, by End-user, 2021–2031

Figure 64: Middle East & Africa CAR T-Cell Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 65: Middle East & Africa CAR T-Cell Therapy Market Value Share (%), by Country/Sub-region, 2020 and 2031

Figure 66: Middle East & Africa CAR T-Cell Therapy Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 67: Middle East & Africa CAR T-Cell Therapy Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 68: Middle East & Africa CAR T-Cell Therapy Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 69: Middle East & Africa CAR T-Cell Therapy Market Value Share Analysis, by Indication, 2020 and 2031

Figure 70: Middle East & Africa CAR T-Cell Therapy Market Attractiveness Analysis, by Indication, 2021–2031

Figure 71: Middle East & Africa CAR T-Cell Therapy Market Value Share Analysis, by End-user, 2020 and 2031

Figure 72: Middle East & Africa CAR T-Cell Therapy Market Attractiveness Analysis, by End-user, 2021–2031

Figure 73: Pfizer, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020

Figure 74: Pfizer, Inc., Breakdown of Net Sales (%), by Biopharma Segment, 2020

Figure 75: Pfizer, Inc., Breakdown of Net Sales (%) Region/Country, 2020

Figure 76: Pfizer, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2020

Figure 77: Novartis AG, Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020

Figure 78: Novartis AG, Revenue Breakdown of Net Sales (%), by Business Segment, 202

Figure 79: Novartis AG, Breakdown of Net Sales (%), by Region/Country, 2020

Figure 80: Novartis AG, R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017–2020

Figure 81: Bristol-Myers Squibb, Revenue (US$ Mn) and Y-o-Y Growth (%), 2017 –2020

Figure 82: Bristol-Myers Squibb, Breakdown of Net Sales (%), by Region/Country, 2020

Figure 83: Bristol-Myers Squibb, R&D Expenses (US$ Mn) 2017–2020

Figure 84: Amgen, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2020

Figure 85: Amgen, Inc. Breakdown of Net Sales (%), by Region/Country, 2020

Figure 86: Amgen, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017-2020

Figure 87: Sorrento Therapeutics, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2020

Figure 88: Sorrento Therapeutics, Inc. Breakdown of Net Sales (%), by Business Segment, 2020

Figure 89: Sorrento Therapeutics, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017-2020

Figure 90: Johnson & Johnson Services, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020

Figure 91: Johnson & Johnson Services, Inc., Breakdown of Net Sales (%), by Business Segment (Pharmaceutical), 2020

Figure 92: Johnson & Johnson Services, Inc., Breakdown of Net Sales (%), by Region/Country, 2020

Figure 93: Johnson & Johnson Services, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth, 2017–2020

Figure 94: Gilead Sciences, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2017-2020

Figure 95: Gilead Sciences, Inc., Breakdown of Net Sales (%), by Region/Country, 2020

Figure 96: Gilead Sciences, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2017-2020

Figure 97: Merck & Co., Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020

Figure 98: Merck & Co., Inc., Breakdown of Net Sales (%), by Business Segment, 2020

Figure 99: Merck & Co., Inc., Breakdown of Net Sales (%), by Region/Country, 2020

Figure 100: Merck & Co., Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth, 2017–2020

Figure 101: bluebird bio, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2017–2020

Figure 102: bluebird bio, Inc., R&D Expenses (US$ Mn) and Y-o-Y Growth, 2017–2020

List of Tables

List of Tables

Table 01: Global Car T-Cell Therapy Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 02: Global Car T-Cell Therapy Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 03: Global Car T-Cell Therapy Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 04: Global Car T-Cell Therapy Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 05: North America CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 06: North America CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 07: North America CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 08: North America CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 09: Europe CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 10: Europe CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 11: Europe CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 12: Europe CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 13: Asia Pacific CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Asia Pacific CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 15: Asia Pacific CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 16: Asia Pacific CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 17: Latin America CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 18: Latin America CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 19: Latin America CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 20: Latin America CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 21: Middle East & Africa CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Middle East & Africa CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 23: Middle East & Africa CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 24: Middle East & Africa CAR T-Cell Therapy Market Value (US$ Mn) Forecast, by End-user, 2017–2031